ClinicalTrials.Veeva

Menu

Treatment of Fecal Incontinence and Functional Evacuation Disorders Using Non-instrumental Biofeedback

V

Vall d'Hebron University Hospital (HUVH)

Status

Enrolling

Conditions

Outlet Dysfunction Constipation
Fecal Incontinence

Treatments

Behavioral: Biofeedback
Behavioral: Placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT06273046
PR(AG)614/2023

Details and patient eligibility

About

Background. Rehabilitation and re-education using instrumental anorectal biofeedback are the main treatment of anorectal functional disorders producing incontinence and outlet obstructed defecation. These treatments imply intubation of patient and several sessions of treatment leading to high consumption of resources and costs.

Hypothesis. A cognitive intervention based on original audiovisual programs developed specifically for the management of anorectal functional disorders is effective in correcting anorectal function disorders that cause fecal incontinence and evacuation disorders.

Aim. To prove in two different protocols (fecal incontinence and dyssinergic defecation) the efficacy of specifically developed non-instrumental biofeedback techniques.

Selection criteria. Patients with fecal incontinence and altered sphincter function and patients with outlet obstructed evacuation referred for biofeedback treatment.

Intervention. In separate studies (incontinence and dyssynergic defecation) patients will be randomized into biofeedback and placebo groups. One session of either biofeedback or placebo intervention will be performed at the beginning of the intervention period and patients will be instructed to performed the assigned daily treatment at home. A visit for outcome assessment will be performed at 3 months in incontinence study and at 4 weeks in the dyssinergic defecation study. In addition, in the incontinence study a phone call will be performed after 6 months of the beginning of the study to evaluate treatment outcome.

Biofeedback: patients will be taught to control anal and abdominal muscular activity by providing instructions using original video supports. Patients will be instructed to perform the same exercises daily at home in scheduled times.

Placebo: a pill of placebo containing 0.3 g glucose will be administered every day at home.

Enrollment

96 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Incontinence studies

  • Patients who have at least 4 episodes of fecal incontinence during the last 14 days.
  • Patients able to follow instructions and attend study visits.

Dyssinergic defecation studies

  • Patients with constipation who present less than 3 complete spontaneous bowel movements per week and/or who have Bristol 1 or Bristol 2 type stools in more than 25% of the bowel movements in the 2 weeks prior to the study
  • Patients able to follow instructions and attend study visits.

Exclusion criteria

  • Patients with organic digestive diseases such as inflammatory bowel disease, celiac disease, gastro-duodenal ulcer...
  • Patients with neurological diseases (spinal cord injury, multiple sclerosis, Parkinson's disease).
  • Patients with previous of active colon and/or rectal cancer.
  • Patients with rectal fistula.
  • Patients with rectal prolapse.
  • Patients with total colectomy.
  • Patients who have had any radiation to the pelvis in the last month.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

96 participants in 2 patient groups, including a placebo group

Biofeedback
Experimental group
Treatment:
Behavioral: Biofeedback
Placebo
Placebo Comparator group
Treatment:
Behavioral: Placebo

Trial contacts and locations

1

Loading...

Central trial contact

Jordi Serra, MD; Gloria Santaliestra

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems